Covid-19 And Influenza Combination
Vaccine Study
CIC-E-301
STUDY OUTLINE
Help us test a COVID-19 and Influenza Combination vaccine for adults
Remuneration: Your travel and time will be reimbursed
This Phase 3 clinical trial sponsored by Novavax will evaluate the Safety and Immunogenicity of a COVID-19 Influenza Combination Nanoparticle Vaccine and a Standalone Nanoparticle Influenza Vaccine
To find out if this trial is suitable for you, please register below, or contact our Clinical Trials Team on 6151 0838 or email clinicaltrials@resphealth.uwa.edu.au.
ELIGIBILITY & REQUIREMENTS
- Healthy adults ≥ 65 years of age
- Participants must have completed a primary vaccination series/booster against COVID-19 with receipt of the last dose of approved vaccine ≥ eight weeks prior to vaccination
WHAT'S INVOLVED
- The trial will run for approximately 182 days (26 weeks)
- Combination of clinic visits and phone visits to the Institute for Respiratory Health at Harry Perkins
PRINCIPAL INVESTIGATOR
Dr David Manners
